

Supplementary references

- S31. Kopec JA, Abrahamowicz M, Esdaile JM. Randomized discontinuation trials: utility and efficiency. *J Clin Epidemiol* 1993;46(9):959-71. doi: 10.1016/0895-4356(93)90163-u [published Online First: 1993/09/01]
- S32. Wallerstedt SM, Hoffmann M. Evidence synthesis based on non-randomised studies-a critical review of studies leading to conclusions on fall risk properties of loop diuretics/beta-blockers. *European Journal of Clinical Pharmacology* 2019;75(12):1731-38. doi: 10.1007/s00228-019-02754-6 [published Online First: 2019/10/11]
- S33. Moscibrodzki P, Katz CL. Application for Inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE. 2018 [Available from: Available at https://www.who.int/selection_medicines/committees/expert/22/applications/methylphenidate/en/].
- S34. Storebø OJ, C G. Public comment on the application for inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE. 2019 https://www.who.int/selection_medicines/committees/expert/22/applications/methylphenidate/en/
- S35. Boesen K, Saiz LC, Erviti J, et al. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. *Evid Based Med* 2017;22(4):143-47. doi: 10.1136/ebmed-2017-110716 [published Online First: 2017/07/15]
- S36. Punja S, Shamseer L, Hartling L, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane Database Syst Rev* 2016;2:Cd009996. doi: 10.1002/14651858.CD009996.pub2 [published Online First: 2016/02/05]
- S37. Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev* 2018;8:Cd007813. doi: 10.1002/14651858.CD007813.pub3 [published Online First: 2018/08/10]
- S38. Ruiz-Goikoetxea M, Cortese S, Aznarez-Sanado M, et al. Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: A systematic review and meta-analysis. *Neurosci Biobehav Rev* 2018;84:63-71. doi: 10.1016/j.neubiorev.2017.11.007 [published Online First: 2017/11/23]
- S39. Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome. *Cochrane Database Syst Rev* 2017;2:Mr000033. doi: 10.1002/14651858.MR000033.pub3 [published Online First: 2017/02/17]
- S40. WHO. Expert Committee on Selection and Use of Essential Medicines. The Selection and Use of Essential Medicines. The 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children. Section 24: Medicines for mental and behavioural disorders. Methylphenidate – addition – EML and EMLc. : World Health Organization; 2019 [Available from: available at <https://www.who.int/medicines/publications/essentialmedicines/en/>].
- S41. Culpepper L, Fried R. Attention-deficit/hyperactivity disorder in a chronic care paradigm. *Postgraduate Medicine* 2013;125(4):78-86.